MESOBLAST LTD
Mesoblast is a commercial-stage biotechnology company that develops cell-based medicines for patients with serious medical conditions, including immune-mediated, cardiovascular, oncology and haematology, and spine and orthopaedic diseases. Its products are based on mesenchymal lineage cells collected from healthy adult donors and expanded using proprietary processes. Ryoncil (remestemcel-L-rknd) is commercially available in the United States for children 2 months and older with steroid-refractory acute graft-versus-host disease. Other product candidates include rexlemestrocel-L, which is being studied for chronic low back pain associated with degenerative disc disease and for heart failure. Mesoblast collaborates with research centers and conducts research and clinical development through in-house laboratories and specialists. It earns money from commercial product sales and also provides product or financial support for independent research studies. Some business functions, including manufacturing, are outsourced to third-party providers. Mesoblast is headquartered in Melbourne, Victoria, Australia.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $MESO in the last 7 days.
No SEC Form 4 filings for $MESO in the last 30 days.
See all $MESO insider activity →Mesoblast Ltd (MESO) announced changes to its Board of Directors, including retirements and new appointments with biopharmaceutical expertise. The company's P/S ratio is 16.5, below its historical median of 48.0x. Insiders have purchased $37.6M in shares over the past year. Mesoblast specializes in regenerative medicine and has a market cap of $2.07B.
Healthcare stocks rose after quarterly updates. Glaukos (GKOS) surged 33% on raised 2026 sales guidance and preliminary 2027 outlook. Teladoc (TDOC) gained 30% despite revenue decline, citing improved EBITDA. Bausch Health (BHC) advanced 26% on higher revenue and earnings. Mesoblast (MESO) jumped 16% on strong Ryoncil revenue growth and clinical updates.
Mesoblast reported an 86% drop in operating cash spending to $2.1M. Sales of Ryoncil® grew, and trials for rexlemestrocel-L in chronic pain and cardiovascular diseases advanced. FDA confirmed a BLA filing for rexlemestrocel-L in end-stage heart failure. The company met with FDA to discuss treatment for life-threatening gastrointestinal bleeding. Mesoblast is listed on Nasdaq (MESO) and ASX (MSB).
Recent MESO coverage spans earnings, financial news and technology.
Board restructuring may create short‑term uncertainty and modest downside pressure.
Strong product revenue and trial progress may fuel further rally.
Cash efficiency improvement and clinical trial advances may lift sentiment.
Revenue miss may pressure the stock despite EPS beat.
Positive regulatory win may boost sales and market confidence.
AlphAI scores every news story that mentions MESO with an AI model for sentiment and relevance, and aggregates insider trades from MESOBLAST LTD's SEC EDGAR Form 4 filings. Figures refresh continuously.
Mesoblast Ltd (MESO) announced changes to its Board of Directors, including retirements and new appointments with biopharmaceutical expertise. The company's P/S ratio is 16.5, below its historical median of 48.0x. Insiders have purchased $37.6M in shares over the past year. Mesoblast specializes in regenerative medicine and has a market cap of $2.07B.
Healthcare stocks rose after quarterly updates. Glaukos (GKOS) surged 33% on raised 2026 sales guidance and preliminary 2027 outlook. Teladoc (TDOC) gained 30% despite revenue decline, citing improved EBITDA. Bausch Health (BHC) advanced 26% on higher revenue and earnings. Mesoblast (MESO) jumped 16% on strong Ryoncil revenue growth and clinical updates.
Mesoblast reported an 86% drop in operating cash spending to $2.1M. Sales of Ryoncil® grew, and trials for rexlemestrocel-L in chronic pain and cardiovascular diseases advanced. FDA confirmed a BLA filing for rexlemestrocel-L in end-stage heart failure. The company met with FDA to discuss treatment for life-threatening gastrointestinal bleeding. Mesoblast is listed on Nasdaq (MESO) and ASX (MSB).
Mesoblast reported FY GAAP EPS of -$0.04, beating estimates by $0.08, while revenue of $120.25M missed by $65.62M. Revenue grew 599.1% year-over-year. The company also received FDA approval for a new potency assay for Ryoncil.
Several biotech and pharma companies received regulatory approvals. MESO, LLY, ANIP, GRAL, AZN, TLSI, ABBV, RHHBY, MRK, AMRX, and ABEO gained approvals for various treatments. ABBV and RHHBY also announced strategic partnerships. LLY, GRAL, and ABBV saw notable stock price changes.
Mesoblast (NASDAQ: MESO, ASX: MSB) completed patient treatment in its Phase 3 trial for rexlemestrocel-L, a therapy for chronic low back pain, with 350 patients enrolled. The company reported US$36M in Q4 revenue for Ryoncil, totaling US$115M for the year. Mesoblast also secured US$103M in cash after extinguishing debt. The company is pursuing FDA approvals for expanded uses of Ryoncil and rexlemestrocel-L.
In 2024-2026, longevity advancements include FDA-approved MSC products, accelerated peptide approvals, and AI-designed drugs. GLP-1 medicines show cardiometabolic benefits. A gray market of wellness peptides exists, with FDA advisory votes on compounding. Mesoblast's Ryoncil gained FDA approval, and Longeveron's Laromestrocel targets aging-related conditions. Life Biosciences initiated a partial cellular reprogramming trial. Key players include Altos Labs, NewLimit, and Life Biosciences, with va
Mesoblast is conducting trials for RYONCIL in acute GVHD and Duchenne muscular dystrophy, with results expected in 2027. The company anticipates double-digit revenue growth and is pursuing approvals for rexlemestrocel-L in chronic low back pain and REVASCOR in heart failure. Mesoblast expects lower cash burn in fiscal 2027 and has a $125M credit facility.
MESOBLAST LTD (MESO) furnished an SEC Form 6-K — earnings release. MESOBLAST REPORTS SUBSTANTIAL REVENUE GROWTH TO US$120M RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment Financial Results and Operational Update for Full Year Ended June 30, 2026 New York, USA: August 26 and Melbourne, Australia: August 27, 2026: Mesobla
Mesoblast (MESO) shares rose about 9.5% after the company said it completed patient treatment in the MSB-DR004 pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain from degenerative disc disease. The trial enrolled 350 patients versus 300 planned. The primary endpoint targets durable pain reduction at 12 months, with FDA RMAT designation and a BLA submission targeted for Q3 2027.
